US Stock MarketDetailed Quotes
RSLS ReShape Lifesciences
- 0.1762
- +0.0058+3.40%
Close May 17 16:00 ET
- 0.1780
- +0.0018+1.02%
Post 19:40 ET
4.13MMarket Cap-400P/E (TTM)
0.2299High0.1714Low6.38MVolume0.1900Open0.1704Pre Close1.28MTurnover30.67%Turnover RatioLossP/E (Static)23.46MShares2.760052wk High0.91P/B3.66MFloat Cap0.141452wk Low--Dividend TTM20.79MShs Float80136000.0000Historical High--Div YieldTTM34.33%Amplitude0.1414Historical Low0.2000Avg Price1Lot Size
ReShape Lifesciences Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -22.79%8.68M | -36.27%1.98M | -22.98%2.16M | -22.06%2.25M | -6.27%2.29M | -17.35%11.24M | -1.02%3.11M | -24.54%2.8M | -18.05%2.89M | -24.25%2.44M |
| Operating revenue | -22.79%8.68M | -36.27%1.98M | -22.98%2.16M | -22.06%2.25M | -6.27%2.29M | -17.35%11.24M | -1.02%3.11M | -24.54%2.8M | -18.05%2.89M | -24.25%2.44M |
| Cost of revenue | -29.47%3.13M | -90.73%140K | 24.39%867K | 5.05%1.06M | -13.01%1.06M | -15.50%4.44M | 10.54%1.51M | -55.69%697K | -26.67%1.01M | 30.42%1.22M |
| Gross profit | -18.44%5.55M | 15.13%1.84M | -38.70%1.29M | -36.59%1.19M | 0.49%1.22M | -18.52%6.8M | -9.91%1.6M | -1.59%2.1M | -12.54%1.88M | -46.67%1.22M |
| Operating expense | -40.42%20.19M | -45.30%3.74M | -37.02%4.39M | -51.58%5.2M | -26.54%6.86M | -4.78%33.88M | -15.29%6.83M | -59.27%6.97M | 83.54%10.75M | 105.48%9.33M |
| Selling and administrative expenses | -42.98%17.87M | -52.94%3M | -39.76%3.85M | -53.78%4.62M | -25.44%6.4M | -5.63%31.34M | -19.78%6.37M | -58.91%6.39M | 73.84%10M | 116.27%8.59M |
| -Selling and marketing expense | -46.44%7.55M | -35.19%1.4M | -31.25%1.79M | -53.04%2.18M | -53.52%2.18M | 58.47%14.09M | -20.32%2.16M | -25.49%2.61M | 221.72%4.64M | 275.52%4.69M |
| -General and administrative expense | -40.15%10.32M | -62.02%1.6M | -45.61%2.06M | -54.41%2.45M | 8.43%4.22M | -29.07%17.25M | -19.51%4.21M | -68.60%3.78M | 24.40%5.36M | 43.09%3.89M |
| Research and development costs | -8.75%2.32M | 59.96%739K | -7.03%542K | -22.22%581K | -39.19%453K | 7.09%2.54M | 272.58%462K | -62.89%583K | 625.24%747K | 30.47%745K |
| Operating profit | 45.94%-14.64M | 63.78%-1.9M | 36.30%-3.1M | 54.77%-4.01M | 30.59%-5.63M | 0.57%-27.08M | 16.81%-5.23M | 67.49%-4.87M | -139.41%-8.86M | -259.46%-8.11M |
| Net non-operating interest income expense | 123.01%26K | 110.63%17K | -83.87%5K | -35.71%9K | -600.00%-5K | 86.42%-113K | -471.43%-160K | 193.94%31K | 108.14%14K | 100.17%1K |
| Non-operating interest income | ---- | ---- | -83.87%5K | -35.71%9K | ---- | ---- | ---- | --31K | --14K | --1K |
| Non-operating interest expense | ---- | ---- | ---- | ---- | --5K | ---- | ---- | ---- | ---- | ---- |
| Total other finance cost | -123.01%-26K | ---- | ---- | ---- | ---- | --113K | ---- | ---- | ---- | ---- |
| Other net income (expense) | 116.89%3.28M | 101.90%211K | 94.38%-433K | 187.20%511K | 10,966.67%2.99M | 45.12%-19.4M | 63.68%-11.13M | -184.26%-7.71M | -586K | 101.35%27K |
| Gain on sale of security | 2,865.96%3.9M | -70.25%97K | 223.30%344K | 331.37%472K | 18,562.50%2.99M | 94.67%-141K | 16,400.00%326K | 89.71%-279K | -301.98%-204K | 148.48%16K |
| Special income (charges) | 96.14%-744K | --0 | 89.54%-777K | 108.66%33K | ---- | 41.08%-19.27M | 62.61%-11.46M | ---7.43M | -277.23%-381K | ---- |
| -Less:Impairment of capital assets | -95.85%777K | --0 | -89.54%777K | ---- | ---- | -38.84%18.74M | -63.08%11.32M | --7.43M | ---- | ---- |
| -Gain on sale of property,plant,equipment | 106.24%33K | --0 | --0 | 108.66%33K | ---- | ---529K | ---146K | ---1K | ---381K | ---- |
| Other non- operating income (expenses) | 1,009.09%122K | 5,600.00%114K | ---- | 700.00%6K | -81.82%2K | --11K | --2K | ---- | ---1K | --11K |
| Income before tax | 75.67%-11.34M | 89.91%-1.67M | 71.86%-3.53M | 63.02%-3.49M | 67.25%-2.65M | 26.53%-46.59M | 55.30%-16.53M | 29.22%-12.55M | -143.55%-9.44M | -66.74%-8.09M |
| Income tax | 113.68%52K | 155.36%31K | 100.83%3K | -55.56%4K | -53.33%14K | -38.69%-380K | 81.14%-56K | -1,110.00%-363K | -67.86%9K | 20.00%30K |
| Net income | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M | 31.15%-12.19M | -142.03%-9.44M | -66.50%-8.12M |
| Net income continuous Operations | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M | 31.15%-12.19M | -142.03%-9.44M | -66.50%-8.12M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M | 31.15%-12.19M | -142.03%-9.44M | -66.50%-8.12M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M | 31.15%-12.19M | -142.03%-9.44M | -66.50%-8.12M |
| Basic earnings per share | 98.25%-1.91 | 99.79%-0.0724 | 96.22%-1.02 | 95.58%-1.08 | 92.87%-1.56 | 62.31%-108.9 | 65.85%-35.11 | 48.06%-27.01 | 43.14%-24.45 | 64.73%-21.87 |
| Diluted earnings per share | 98.25%-1.91 | 99.79%-0.0724 | 96.22%-1.02 | 95.58%-1.08 | 92.87%-1.56 | 62.31%-108.9 | 65.85%-35.11 | 48.06%-27.01 | 43.14%-24.45 | 64.73%-21.87 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg